189955-81-5Relevant articles and documents
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
-
, (2008/06/13)
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors
Li, Chun-Sing,Black, W. Cameron,Brideau, Christine,Chan, Chi Chung,Charleson, Stella,Cromlish, Wanda A.,Claveau, David,Yves Gauthier, Jacques,Gordon, Robert,Greig, Gillian,Grimm, Erich,Guay, Jocelyne,Lau, Cheuk K.,Riendeau, Denis,Therien, Michel,Visco, Denise M.,Wong, Elizabeth,Xu, Lijing,Prasit, Petpiboon
, p. 3181 - 3186 (2007/10/03)
By inserting an oxygen link between the 3-fluorophenyl and the lactone ring of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methanesulfonylphenyl)-2(5H)-furanone 1 (DFU), analogs with enhanced in vitro COX-2 inhibitory potency as well as in vivo potency in models of inflammation were obtained.
Alkylated styrenes as prodrugs to COX-2 inhibitors
-
, (2008/06/13)
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
